Glycoprotein N of Human Cytomegalovirus Protects the Virus from Neutralizing Antibodies

PLoS Pathogens

Volumn 8, Issue 10, 2012, Pages

  Kropff, Barbara ^a   Burkhardt, Christiane ^a,c   Schott, Juliane ^a,d   Nentwich, Jens ^a,e   Fisch, Tanja ^a,f   Britt, William ^b   Mach, Michael ^a  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^b University of Alabama at Birmingham   (United States)

^c Institute of Experimental Immunology   (Germany)

^d HANNOVER MEDICAL SCHOOL   (Germany)

^e KLINIKUM NÜRNBERG   (Germany)

^f Amgen Research   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOPROTEIN; GLYCOPROTEIN B; GLYCOPROTEIN N; MONOCLONAL ANTIBODY; NEUTRALIZING ANTIBODY; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; ANIMAL EXPERIMENT; ANTIBODY TITER; ARTICLE; CONTROLLED STUDY; GLYCOSYLATION; HUMAN CYTOMEGALOVIRUS; IMMUNIZATION; MOUSE; NONHUMAN; VIRUS NEUTRALIZATION; VIRUS REPLICATION; VIRUS RESISTANCE; VIRUS STRAIN;

AMINO ACID SEQUENCE; ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; CELL LINE; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; GLYCOSYLATION; HEK293 CELLS; HUMANS; IMMUNE EVASION; IMMUNIZATION; MICE; MICE, INBRED BALB C; MOLECULAR SEQUENCE DATA; MUTATION; NEUTRALIZATION TESTS; SEQUENCE DELETION; VIRAL ENVELOPE PROTEINS;

ANIMALIA; HERPESVIRIDAE; HUMAN HERPESVIRUS 5; MUS;

EID: 84868089363     PISSN: 15537366     EISSN: 15537374     Source Type: Journal    
DOI: 10.1371/journal.ppat.1002999     Document Type: Article

References (67)

1. Jackson SE, Mason GM, Wills MR, (2011) Human cytomegalovirus immunity and immune evasion. Virus Res 157: 151-160.
2. Reddehase MJ, (2002) Antigens and immunoevasins: opponents in cytomegalovirus immune surveillance. Nat Rev Immunol 2: 831-844.
3. Babic M, Krmpotic A, Jonjic S, (2011) All is fair in virus-host interactions: NK cells and cytomegalovirus. Trends Mol Med 17: 677-685.
4. Renzette N, Bhattacharjee B, Jensen JD, Gibson L, Kowalik TF, (2011) Extensive genome-wide variability of human cytomegalovirus in congenitally infected infants. PLoS Pathog 7 (5) (): e1001344.
5. Smith LM, Shellam GR, Redwood AJ, (2006) Genes of murine cytomegalovirus exist as a number of distinct genotypes. Virology 352: 450-465.
6. Hansen SG, Powers CJ, Richards R, Ventura AB, Ford JC, et al. (2010) Evasion of CD8+ T cells is critical for superinfection by cytomegalovirus. Science 328: 102-106.
7. Ross SA, Arora N, Novak Z, Fowler KB, Britt WJ, et al. (2010) Cytomegalovirus reinfections in healthy seroimmune women. J Infect Dis 201: 386-389.
8. Gorman S, Harvey NL, Moro D, Lloyd ML, Voigt V, et al. (2006) Mixed infection with multiple strains of murine cytomegalovirus occurs following simultaneous or sequential infection of immunocompetent mice. J Gen Virol 87: 1123-1132.
9. Yamamoto AY, Mussi-Pinhata MM, Boppana SB, Novak Z, Wagatsuma VM, et al. (2010) Human cytomegalovirus reinfection is associated with intrauterine transmission in a highly cytomegalovirus-immune maternal population. Am J Obstet Gynecol 202: 297-298.
10. Ishibashi K, Tokumoto T, Tanabe K, Shirakawa H, Hashimoto K, et al. (2007) Association of the outcome of renal transplantation with antibody response to cytomegalovirus strain-specific glycoprotein H epitopes. Clin Infect Dis 45: 60-67.
11. Klein M, Schoppel K, Amvrossiadis N, Mach M, (1999) Strain-specific neutralization of human cytomegalovirus isolates by human sera. J Virol 73: 878-886.
12. Burkhardt C, Himmelein S, Britt W, Winkler T, Mach M, (2009) Glycoprotein N subtypes of human cytomegalovirus induce a strain-specific antibody response during natural infection. J Gen Virol 90: 1951-1961.
13. Speckner A, Glykofrydes D, Ohlin M, Mach M, (1999) Antigenic domain 1 of human cytomegalovirus glycoprotein B induces a multitude of different antibodies which, when combined, results in incomplete virus neutralization. J Gen Virol 80: 2183-2191.
14. Ohlin M, Sundqvist VA, Mach M, Wahren B, Borrebaeck CA, (1993) Fine specificity of the human immune response to the major neutralization epitopes expressed on cytomegalovirus gp58/116 (gB), as determined with human monoclonal antibodies. J Virol 67: 703-710.
15. Vigerust DJ, Shepherd VL, (2007) Virus glycosylation: role in virulence and immune interactions. Trends Microbiol 15: 211-218.
16. Pellet P., Roizman B. (2007) The family Herpesviridae: A brief introductioon. In: Knipe D.M., Howley P.M., editors. Fields Virology. Lipppincott Williams. pp. 2479-2501.
17. Liang X, Tang M, Manns B, Babiuk LA, Zamb TJ, (1993) Identification and deletion mutagenesis of the bovine herpesvirus 1 dUTPase gene and a gene homologous to herpes simplex virus UL49.5. Virology 195: 42-50.
18. Jons A, Dijkstra JM, Mettenleiter TC, (1998) Glycoproteins M and N of pseudorabies virus form a disulfide-linked complex. J Virol 72: 550-557.
19. Mach M, Osinski K, Kropff B, Schloetzer-Schrehardt U, Krzyzaniak M, et al. (2007) The carboxy-terminal domain of glycoprotein N of human cytomegalovirus is required for virion morphogenesis. J Virol 81: 5212-5224.
20. Ross J, Williams M, Cohen JI, (1997) Disruption of the varicella-zoster virus dUTPase and the adjacent ORF9A gene results in impaired growth and reduced syncytia formation in vitro. Virology 234: 186-195.
21. Varnum SM, Streblow DN, Monroe ME, Smith P, Auberry KJ, et al. (2004) Identification of proteins in human cytomegalovirus (HCMV) particles: the HCMV proteome. J Virol 78: 10960-10966.
22. Pignatelli S, Dal Monte P, Rossini G, Chou S, Gojobori T, et al. (2003) Human cytomegalovirus glycoprotein N (gpUL73-gN) genomic variants: identification of a novel subgroup, geographical distribution and evidence of positive selective pressure. J Gen Virol 84: 647-655.
23. Mach M, Kropff B, Dal-Monte P, Britt WJ, (2000) Complex formation of human cytomegalovirus gylcoprotein M (gpUL100) and glycoprotein N (gpUl73). J Virol 74: 11881-11892.
24. Adams R, Cunningham C, Davison MD, MacLean CA, Davison AJ, (1998) Characterization of the protein encoded by gene UL49A of herpes simplex virus type 1. J Gen Virol 79 (Pt 4) (): 813-823.
25. Lake CM, Molesworth SJ, Hutt-Fletcher LM, (1998) The Epstein-Barr virus (EBV) gN homolog BLRF1 encodes a 15-kilodalton glycoprotein that cannot be authentically processed unless it is coexpressed with the EBV gM homolog BBRF3. J Virol 72: 5559-5564.
26. Koyano S, Mar EC, Stamey FR, Inoue N, (2003) Glycoproteins M and N of human herpesvirus 8 form a complex and inhibit cell fusion. J Gen Virol 84: 1485-1491.
27. Rawlinson WD, Farrell HE, Barrell BG, (1996) Analysis of the complete DNA sequence of murine cytomegalovirus. J Virol 70: 8833-8849.
28. Vink C, Beuken E, Bruggeman CA, (2000) Complete DNA sequence of the rat cytomegalovirus genome. J Virol 74: 7656-7665.
29. Davison AJ, Dolan A, Akter P, Addison C, Dargan DJ, et al. (2003) The human cytomegalovirus genome revisited: comparison with the chimpanzee cytomegalovirus genome. J Gen Virol 84: 17-28.
30. Hansen SG, Strelow LI, Franchi DC, Anders DG, Wong SW, (2003) Complete sequence and genomic analysis of rhesus cytomegalovirus. J Virol 77: 6620-6636.
31. Marsh AK, Willer DO, Ambagala AP, Dzamba M, Chan JK, et al. (2011) Genomic sequencing and characterization of cynomolgus macaque cytomegalovirus. J Virol 85: 12995-13009.
32. Kari B, Gehrz R, (1992) A human cytomegalovirus glycoprotein complex designated gC-II is a major heparin-binding component of the envelope. J Virol 66: 1761-1764.
33. Compton T, (2004) Receptors and immune sensors: the complex entry path of human cytomegalovirus. Trends Cell Biol 14: 5-8.
34. Shimamura M, Mach M, Britt WJ, (2006) Human cytomegalovirus infection elicits a glycoprotein M (gM)/gN-specific virus-neutralizing antibody response. J Virol 80: 4591-4600.
35. Borst EM, Hahn G, Koszinowski UH, Messerle M, (1999) Cloning of the human cytomegalovirus (HCMV) genome as an infectious bacterial artificial chromosome in Escherichia coli: a new approach for construction of HCMV mutants. J Virol 73: 8320-8329.
36. Mach M, Kropff B, Kryzaniak M, Britt W, (2005) Complex formation by glycoproteins M and N of human cytomegalovirus: structural and functional aspects. J Virol 79: 2160-2170.
37. Sanchez V, Greis KD, Sztul E, Britt WJ, (2000) Accumulation of virion tegument and envelope proteins in a stable cytoplasmic compartment during human cytomegalovirus replication: characterization of a potential site of virus assembly. J Virol 74: 975-986.
38. Simpson JA, Chow JC, Baker J, Avdalovic N, Yuan S, et al. (1993) Neutralizing monoclonal antibodies that distinguish three antigenic sites on human cytomegalovirus glycoprotein H have conformationally distinct binding sites. J Virol 67: 489-496.
39. Compton T, Nowlin DM, Cooper NR, (1993) Initiation of human cytomegalovirus infection requires initial interaction with cell surface heparan sulfate. Virology 193: 834-841.
40. Wei X, Decker JM, Wang S, Hui H, Kappes JC, et al. (2003) Antibody neutralization and escape by HIV-1. Nature 422: 307-312.
41. Knossow M, Skehel JJ, (2006) Variation and infectivity neutralization in influenza. Immunology 119: 1-7.
42. Britt WJ, Vugler L, Butfiloski EJ, Stephens EB, (1990) Cell surface expression of human cytomegalovirus (HCMV) gp55-116 (gB): use of HCMV-recombinant vaccinia virus-infected cells in analysis of the human neutralizing antibody response. J Virol 64: 1079-1085.
43. Urban M, Klein M, Britt WJ, Hassfurther E, Mach M, (1996) Glycoprotein H of human cytomegalovirus is a major antigen for the neutralizing humoral immune response. J Gen Virol 77 (Pt 7) (): 1537-1547.
44. Potzsch S, Spindler N, Wiegers AK, Fisch T, Rucker P, et al. (2011) B cell repertoire analysis identifies new antigenic domains on glycoprotein B of human cytomegalovirus which are target of neutralizing antibodies. PLoS Pathog 7: e1002172.
45. Lantto J, Fletcher JM, Ohlin M, (2002) A divalent antibody format is required for neutralization of human cytomegalovirus via antigenic domain 2 on glycoprotein B. J Gen Virol 83: 2001-2005.
46. Wagner B, Kropff B, Kalbacher H, Britt W, Sundqvist VA, et al. (1992) A continuous sequence of more than 70 amino acids is essential for antibody binding to the dominant antigenic site of glycoprotein gp58 of human cytomegalovirus. J Virol 66: 5290-5297.
47. Meyer H, Sundqvist VA, Pereira L, Mach M, (1992) Glycoprotein gp116 of human cytomegalovirus contains epitopes for strain-common and strain-specific antibodies. J Gen Virol 73: 2375-2383.
48. Urban M, Britt W, Mach M, (1992) The dominant linear neutralizing antibody-binding site of glycoprotein gp86 of human cytomegalovirus is strain specific. J Virol 66: 1303-1311.
49. Landini MP, Guan MX, Jahn G, Lindenmaier W, Mach M, et al. (1990) Large-scale screening of human sera with cytomegalovirus recombinant antigens. J Clin Microbiol 28: 1375-1379.
50. Patrone M, Secchi M, Bonaparte E, Milanesi G, Gallina A, (2007) Cytomegalovirus UL131-128 products promote gB conformational transition and gB-gH interaction during entry into endothelial cells. J Virol 81: 11479-11488.
51. Sinzger C, (2008) Entry route of HCMV into endothelial cells. J Clin Virol 41: 174-179.
52. Rodger G, Boname J, Bell S, Minson T, (2001) Assembly and organization of glycoproteins B, C, D, and H in herpes simplex virus type 1 particles lacking individual glycoproteins: No evidence for the formation of a complex of these molecules. J Virol 75: 710-716.
53. Fleury D, Wharton SA, Skehel JJ, Knossow M, Bizebard T, (1998) Antigen distortion allows influenza virus to escape neutralization. Nat Struct Biol 5: 119-123.
54. Li L, Nelson JA, Britt WJ, (1997) Glycoprotein H-related complexes of human cytomegalovirus: identification of a third protein in the gCIII complex. J Virol 71: 3090-3097.
55. Huber MT, Compton T, (1997) Characterization of a novel third member of the human cytomegalovirus glycoprotein H-glycoprotein L complex. J Virol 71: 5391-5398.
56. Britt WJ, Vugler LG, (1989) Processing of the gp55-116 envelope glycoprotein complex (gB) of human cytomegalovirus. J Virol 63: 403-410.
57. Gillet L, Stevenson PG, (2007) Antibody evasion by the N terminus of murid herpesvirus-4 glycoprotein B. EMBO J 26: 5131-5142.
58. Jiang XJ, Sampaio KL, Ettischer N, Stierhof YD, Jahn G, et al. (2011) UL74 of human cytomegalovirus reduces the inhibitory effect of gH-specific and gB-specific antibodies. Arch Virol 156: 2145-2155.
59. Ma BJ, Alam SM, Go EP, Lu X, Desaire H, et al. (2011) Envelope deglycosylation enhances antigenicity of HIV-1 gp41 epitopes for both broad neutralizing antibodies and their unmutated ancestor antibodies. PLoS Pathog 7: e1002200.
60. Machiels B, Lete C, Guillaume A, Mast J, Stevenson PG, et al. (2011) Antibody evasion by a gammaherpesvirus O-glycan shield. PLoS Pathog 7: e1002387.
61. Andreoni M, Faircloth M, Vugler L, Britt WJ, (1989) A rapid microneutralization assay for the measurement of neutralizing antibody reactive with human cytomegalovirus. J Virol Methods 23: 157-167.
62. Talbot P, Almeida JD, (1977) Human cytomegalovirus: purification of enveloped virions and dense bodies. J Gen Virol 36: 345-349.
63. Schoppel K, Hassfurther E, Britt WJ, Ohlin M, Borrebaeck CA, et al. (1996) Antibodies specific for the antigenic domain 1 (AD-1) of glycoprotein B (gpUL55) of human cytomegalovirus bind to different substructures. Virology 216: 133-145.
64. Meyer H, Masuho Y, Mach M, (1990) The gp116 of the gp58/116 complex of human cytomegalovirus represents the amino-terminal part of the precursor molecule and contains a neutralizing epitope. J Gen Virol 71: 2443-2450.
65. Cherepanov PP, Wackernagel W, (1995) Gene disruption in Escherichia coli: TcR and KmR cassettes with the option of Flp-catalyzed excision of the antibiotic-resistance determinant. Gene 158: 9-14.
66. Muyrers JP, Zhang Y, Benes V, Testa G, Ansorge W, et al. (2000) Point mutation of bacterial artificial chromosomes by ET recombination. EMBO Rep 1: 239-243.
67. Schoppel K, Schmidt C, Einsele H, Hebart H, Mach M, (1998) Kinetics of the antibody response against human cytomegalovirus-specific proteins in allogeneic bone marrow transplant recipients. J Infect Dis 178: 1233-1243.